Phase 4 N=178 Preventing Hypotension in Parturients With an Elevated Body Mass Index (BMI)
Hypotension
Primary: Incidence of Nausea and Vomiting — 59; 37 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=36 Effect of Weight and/or Obesity on Sulfamethoxazole and Trimethoprim Concentrations
Obesity · Pharmacokinetics · MRSA
Primary: Elimination Rate Constants for Sulfamethoxazole and Trimethoprim — 0.060; 0.03 hr-1 — p=0.0004
N/A N=130 Assessment of the Fungal Infection Incidence Across Canada for High Risk Participants With Hematological Disease (P07501)
Mycoses · Leukemia
Primary: Percentage of Participants With Non-Candida Invasive Fungal Infections at a Single Institution — 32.3 Percentage of participants
N/A N=66 Clinical Evaluation of CARESTREAM Dual Energy and Digital Tomosynthesis
Solitary Pulmonary Nodules
Primary: Radlex Scale for Diagnostic Quality Ratings - DE Predicate PA Chest — 3.4540 units on a scale
N/A N=222 Maintenance After Initiation of Nutrition TrAINing
Obesity
Primary: Weight — 99.2; 105.7 kilograms — p=.04
N/A N=11 Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors
Basal Cell Carcinoma
Primary: Progression Free Survival (PFS) of All Participants — 6; 36 weeks
Phase 3 N=463 A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting
Ulcerative Colitis
Primary: Mean Change From Baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ): Total Score — 17.4 units on a scale — p=<0.001
Phase 4 N=77 A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants With No Radiographic Progression at Month 12 — 62.9; 61.5 percentage of participants — p=0.907
N/A N=44 Novel Portable Diagnostic Device for Automatic Detection of Relative Afferent Pupillary Defect
Multiple Sclerosis · Glaucoma
Primary: Number of Participants With Detected Relative Afferent Pupillary Defect (RAPD) — 44; 37 participants
Phase 2 N=88 Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET)
Alzheimer's Disease
Primary: Global Distribution of C11 PiB in the Brain — 2.50; 1.47; 1.23 standard uptake value ratio — p=<0.001
Phase 2 N=17 Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma
Bladder Cancer
Primary: Progression Free Survival (PFS) — 9.5 months
Phase 2 N=20 Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
Mixed Gliomas
Primary: Number of Participants With Objective Response — 3; 0; 4; 10 Participants
N/A N=1,613 A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)
Arthritis, Rheumatoid · Arthritis, Psoriatic · Spondylitis, Ankylosing
Primary: Clinical Global Impression (CGI) Disease Status — 5.7; 5.5; 5.7; 3.4 Units on a scale
Phase 4 N=15 Effect of hCG on Receptivity of the Human Endometrium
Infertility · Subfertility
Primary: Endometrial Staging in hCG Versus Vehicle Treated Patients — 4.0; 4.6; 3.9; 6.5 days — p=<0.05
Phase 3 N=125 Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.
Gastrointestinal Stromal Tumors
Primary: Percent of Patients Achieving Stable Disease (SD) — 48.8 % participants